Market cap
₹342 Cr
Revenue (TTM)
₹145 Cr
P/E Ratio
23.6
P/B Ratio
-48.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹14 Cr
-
ROE
0 %
-
ROCE
72 %
-
Industry P/E
60.11
-
EV/EBITDA
13.9
-
Debt to Equity
4.1
-
Book Value
₹5.3
-
EPS
₹14.5
-
Face value
10
-
Shares outstanding
10,024,242
10 Years Aggregate
CFO
₹92.30 Cr
EBITDA
₹-7.48 Cr
Net Profit
₹-57.58 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Wintac
| 267.5 | 37.2 | 62.7 | 302.1 | 16.2 | -0.3 | 24.6 |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
BSE Healthcare#
| 18.7 | 1.7 | 10.2 | 18.2 | 22.8 | 14.5 | 12.3 |
|
Company
|
2019
|
2018
|
2017
|
2016
|
2015
|
2014
|
|---|---|---|---|---|---|---|
|
Wintac
| -54.2 | -1.9 | 33.5 | -50.8 | 49.4 | 141.6 |
|
BSE Sensex
| 14.4 | 5.9 | 27.9 | 1.9 | -5.0 | 29.9 |
|
BSE Healthcare
| -3.5 | -5.9 | 0.5 | -12.9 | 15.1 | 47.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Wintac
|
341.6 | 342.4 | 145.0 | 14.5 | 1.8 | 0 | 23.6 | -48.8 |
| 3,160.6 | 25,815.6 | 1,461.8 | 387.4 | 34.5 | 25.2 | 66.8 | 14.9 | |
| 834.9 | 16,429.7 | 7,784.0 | 688.5 | 10.6 | 14 | 23.7 | 2.8 | |
| 456.0 | 17,456.0 | 2,141.5 | 58.5 | 5.8 | 3.3 | 164.3 | 4.5 | |
| 828.5 | 20,518.8 | 5,632.3 | 662.4 | 17.2 | 14.3 | 31 | 4.2 | |
| 1,519.1 | 17,370.7 | 1,543.3 | -48.6 | 3.6 | -0.6 | -- | 3.0 | |
| 214.4 | 28,550.8 | 9,205.3 | -371.8 | 1.7 | -3.8 | -- | 3.6 | |
| 1,819.6 | 30,087.9 | 1,935.8 | 288.2 | 20.6 | 29.8 | 104.4 | 22.4 | |
| 400.8 | 16,183.1 | 3,600.2 | 221.0 | 9.7 | 5.6 | 73.2 | 3.4 | |
| 1,883.7 | 30,606.2 | 3,564.0 | 414.0 | 15.3 | 8.4 | 74.8 | 6.1 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Wintac
Wintac Limited develops, manufactures, and sells pharmaceutical formulations in India. It offers a range of ophthalmic products; and injectable products, such as large and small volume parental products. The company was formerly known as Recon... Limited and changed its name to Wintac Limited in 2001. The company was founded in 1987 and is based in Bengaluru, India. Wintac Limited is a subsidiary of Veego Pharma LLC. Read more
-
Incorporated
1990
-
Chairman
K Paranjothy
-
Managing Director
--
-
Group
MNC
-
Headquarters
Bengaluru, Karnataka
-
Website
Looking for more details about Wintac Ltd.’s IPO? Explore our IPO Details page.
FAQs for Wintac
What is the current share price of Wintac Ltd Today?
The share price of Wintac Ltd is ₹341.60 (BSE) as of 17-Dec-2020 IST. Wintac Ltd has given a return of 16.17% in the last 3 years.
What is the current PB & PE ratio of Wintac Ltd?
The P/E ratio of Wintac Ltd is 23.63 times as on 17-Dec-2020, a 61 discount to its peers’ median range of 60.11 times.
The P/B ratio of Wintac Ltd is -48.85 times as on 17-Dec-2020, a 1346 discount to its peers’ median range of 3.92 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2021 |
0.00 |
0.00 |
2020 |
0.00 |
-19.83 |
2019 |
1,841.91 |
-45.85 |
2018 |
0.00 |
-46.72 |
2017 |
0.00 |
30.04 |
What is the 52 Week High and Low of Wintac Ltd?
The 52-week high and low of Wintac Ltd are Rs -- and Rs -- as of 01-Sep-2026.
What is the market cap of Wintac Ltd?
Wintac Ltd has a market capitalisation of ₹ 342 Cr as on 17-Dec-2020. As per SEBI classification, it is a company.
Should I invest in Wintac Ltd?
Before investing in Wintac Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.